Skip to main content
. 2022 Aug 17;13:920280. doi: 10.3389/fmicb.2022.920280

FIGURE 5.

FIGURE 5

Evaluation of preS1-21-pep3 on HepG2-NTCP cell model. (A) Procedure for the testing of the Myr-peptides (Myr-pep3 or Myr-21) on HepG2-NTCP cell model. HepG2-NTCP cells were pretreated with the Myr-peptides for 2 h and then inoculated with HBV for 16 h. The final concentrations were 0, 1, 5, 10, and 30 nM for Myr-pep3, and 0, 10, 30, 100, and 300 nM for Myr-21. After washing out the free HBV and the Myr-peptides, the cells were cultured with the medium in the absence of Myr-peptide for additional 5 days. (B,C) Secreted HBeAg and HBsAg in the medium were detected by ELISA, and the IC50s were calculated from the dose-effect curves. (D,E) RT-QPCR assay for intracellular HBV pgRNA. Intracellular HBV RNA samples were extracted from the cells and HBV pgRNA was detected by QPCR after reverse transcription. (F) Intracellular HBV RNA assays by northern blot. A part of the intracellular HBV RNA samples from (D,E) were detected by the northern blot.